Maintenance therapy and advanced non-small-cell lung cancer: A skeptic's view

Martin J. Edelman, Thierry Le Chevalier, Jean Charles Soria

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Maintenance chemotherapy has a long history of use in hematologic malignancies, in which the benefits are considerable in terms of survival and quality of life. Recently, several studies have demonstrated that maintenance therapy in non-small-cell lung cancer can prolong overall survival in patients who have benefited from initial platinum-based chemotherapy. These studies have led to regulatory approval of two agents (pemetrexed and erlotinib) in this setting. We raise several issues regarding the design and execution of these studies, which question the validity of these conclusions, and explore aspects of the trial results concerning the optimal use of this approach, if it is to be accepted.

Original languageEnglish
Pages (from-to)1331-1336
Number of pages6
JournalJournal of Thoracic Oncology
Issue number9
StatePublished - Sep 2012
Externally publishedYes


  • Chemotherapy
  • Duration
  • Maintenance
  • Non-small-cell lung cancer


Dive into the research topics of 'Maintenance therapy and advanced non-small-cell lung cancer: A skeptic's view'. Together they form a unique fingerprint.

Cite this